SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 195.32-1.4%12:38 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mudcat who wrote (19021)4/14/1998 9:47:00 AM
From: Henry Niman   of 32384
 
Here is another article from today's NY Times SCIENCE section. I does discuss Tamoxifen itself in more detail and does indicate that the new compound to be tested in the next NCI breast cancer prevention trial is Raloxifene.

However, there is no indication that Raloxifene (an APPROVED SERM for PREVENTING osteoporosis) is actually Evista and is sold by LLY (and presentations at the upcoming ASCO meeting will show that it PREVENTS BREAST CANCER).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News